Tremelimumab (Imjudo) in Combination With Durvalumab (Imfinzi)

Abstract

CADTH recommends that tremelimumab (Imjudo) in combination with durvalumab (Imfinzi) should be reimbursed by public drug plans for the treatment of patients with unresectable hepatocellular carcinoma (HCC) if certain conditions are met. Imjudo in combination with Imfinzi should only be covered to treat adult patients who have confirmed liver cancer that cannot be removed by surgery, are classified as Child-Pugh score class A, and require systemic therapy. Patients should be in relatively good health (i.e., have a good performance status, as determined by a specialist). Imjudo in combination with Imfinzi should only be reimbursed as first-line treatment and should not be given in combination with other systemic anticancer drugs. Imjudo in combination with Imfinzi should be prescribed by clinicians with expertise and experience in treating unresectable HCC. In addition, the price for Imjudo in combination with Imfinzi should be reduced.